-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 12, Tasly issued an announcement stating that the company received the "Drug Supplementary Application Approval Notice" for compound Danshen dripping pills approved and issued by the State Food and Drug Administration.
Fufang Danshen Dripping Pills is a compound Chinese medicine for the treatment of cardiovascular diseases developed exclusively by Tasly.
In 2008, the company submitted a clinical supplementary application (acceptance number: CYZB0803905) for the compound Danshen dripping pill to increase the indications of diabetic retinopathy to the Drug Evaluation Center of the State Food and Drug Administration.
Diabetic retinopathy is an eye disease characterized by retinal microvascular damage caused by diabetes.